Pembrolizumab Plus Weekly Paclitaxel, With Or Without Bevacizumab, Improves OS in Patients With Platinum-Resistant Recurrent Ovarian Cancer By Ogkologos - April 23, 2026 237 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ENGOT-ov65/KEYNOTE-B96 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR HGTV Star Hilary Farr Shares Breast Cancer Battle December 16, 2021 FDA Approves Azacitidine for Newly Diagnosed Juvenile Myelomonocytic Leukaemia June 2, 2022 Maintenance Regorafenib Significantly Delays Disease Progression After First-Line Treatment in Patients... April 28, 2025 Breast Cancer Patient Is Accused of Having “Body Image Issues” After... March 5, 2021 Load more HOT NEWS College Basketball Star Plays First Game in Nearly Two Years After... FDA Approves Palbociclib with Trastuzumab, With or Without Pertuzumab, and Endocrine... Having a Heart Attack May Make Breast Cancer Grow Faster As More People with Cancer Use Medical Cannabis, Oncologists Face Questions...
